We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Discovery of Prognostic Markers for Early-Stage High-Grade Serous Ovarian Cancer by Maldi-Imaging.
- Authors
Kulbe, Hagen; Klein, Oliver; Wu, Zhiyang; Taube, Eliane T.; Kassuhn, Wanja; Horst, David; Darb-Esfahani, Silvia; Jank, Paul; Abobaker, Salem; Ringel, Frauke; du Bois, Andreas; Heitz, Florian; Sehouli, Jalid; Braicu, Elena I.
- Abstract
With regard to relapse and survival, early-stage high-grade serous ovarian (HGSOC) patients comprise a heterogeneous group and there is no clear consensus on first-line treatment. Currently, no prognostic markers are available for risk assessment by standard targeted immunohistochemistry and novel approaches are urgently required. Here, we applied MALDI-imaging mass spectrometry (MALDI-IMS), a new method to identify distinct mass profiles including protein signatures on paraffin-embedded tissue sections. In search of prognostic biomarker candidates, we compared proteomic profiles of primary tumor sections from early-stage HGSOC patients with either recurrent (RD) or non-recurrent disease (N = 4; each group) as a proof of concept study. In total, MALDI-IMS analysis resulted in 7537 spectra from the malignant tumor areas. Using receiver operating characteristic (ROC) analysis, 151 peptides were able to discriminate between patients with RD and non-RD (AUC > 0.6 or < 0.4; p < 0.01), and 13 of them could be annotated to proteins. Strongest expression levels of specific peptides linked to Keratin type1 and Collagen alpha-2(I) were observed and associated with poor prognosis (AUC > 0.7). These results confirm that in using IMS, we could identify new candidates to predict clinical outcome and treatment extent for patients with early-stage HGSOC.
- Subjects
BIOMARKERS; CELL lines; GENE expression; HISTOLOGICAL techniques; MASS spectrometry; OVARIAN tumors; TISSUE arrays
- Publication
Cancers, 2020, Vol 12, Issue 8, p2000
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers12082000